Imiquimod for the treatment of morphea: a systematic review.

Arch Dermatol Res

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.

Published: December 2024

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-024-03620-xDOI Listing

Publication Analysis

Top Keywords

imiquimod treatment
4
treatment morphea
4
morphea systematic
4
systematic review
4
imiquimod
1
morphea
1
systematic
1
review
1

Similar Publications

The stress-induced keratin intermediate filament gene/protein (K16) is spatially restricted to the suprabasal compartment of the epidermis and extensively used as a biomarker for psoriasis, hidradenitis suppurativa, atopic dermatitis and other inflammatory disorders. However, its role in these conditions remains poorly defined. Here we show that K16 negatively regulates type-I interferon (IFN) signaling and innate immune responses.

View Article and Find Full Text PDF

Psoriasis seriously affects the physical and mental health of patients. Rocaglamide (RocA), derived from Aglaia odorata, exhibits potent pharmacological activities. Although its efficacy in psoriasis is unclear, RocA could be a promising therapeutic drug.

View Article and Find Full Text PDF

Exploring the Therapeutic Effects of Anisole on Psoriasis in Mice Based on the JAK1/STAT3 Pathway.

Phytother Res

January 2025

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

Safe and effective treatments for psoriasis are limited. Anisole is an active ingredient in citrus and basil volatile oils; however, its potential for psoriasis treatment remains unexplored. To investigate the effects and mechanism of anisole transdermal administration as a treatment for psoriasis.

View Article and Find Full Text PDF

Rational design and therapeutic potential of MyD88 inhibitory peptide in psoriasis.

Biomed Pharmacother

January 2025

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea; S&K Therapeutics, Ajou University Campus Plaza 418, Worldcup-ro 199, Yeongton-gu, Suwon 16502, Republic of Korea. Electronic address:

Myeloid differentiation primary-response 88 (MyD88) is a crucial adaptor protein for initiating immune responses via Toll-like receptors (TLRs). This study employed a rational peptide design approach to develop MyD88 inhibitory peptides targeting the MyD88 interaction interface. The designed peptide, MyDIP2-4, was evaluated for its efficacy in inhibiting MyD88-dependent signaling in human and mouse cell lines.

View Article and Find Full Text PDF

Objective: actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!